Phone:
Email: michellexu@mail.tsinghua.edu.cn
The Laboratory of Meng Xu
Meng Xu, Ph.D.
Professional Experience
2017 Principal investigator, School of Medicine, Tsinghua University, Beijing, China
2016-2017 Research Assistant Professor, University of Chicago, Chicago, IL, USA
2013-2016 Postdoctoral Scholar, Department of Pathology, University of Chicago, Chicago, IL, USA
2007-2012 PhD in Cell Biology, Institute of Biophysics, Chinese Academy of Science, Beijing, China
2003-2007 Bachelor of Pharmacology, Capital Medical University, Beijing, China
Post-Docs
Chuanyuan Chen
I obtained my PHD degree from Beijing Institute of Genomics Chinese Academy of Science in 2021, majored in bioinformatics. My research area is epigenetic modification and antitumor immuntherapy.
Ph.D. students
Lihui Dong
Immune cell crosstalk within tumor microenvironment
Wenxin Dong
She graduated from Tsinghua University with her bachelor’s degree. Currently, her study focuses on investigating the impact of m6A reader protein on T cells.
Yilin Li
His research focuses on the effect of RNA m6A modification on myeloid cells in anti-tumor immune response. He would like to discover the interaction between antigen presenting cells and T cells during tumor immune response.
Shibo Liu
Yi Liu
Cell-cell interaction during tumor immune response.
Zhiwei Qiu
Zhiwei Qiu, Ph.D student (from 2020) in School of Medicine, Bachelor’s degree from Tsinghua University, School of Life Sciences. He joined Meng Michelle Xu’s lab in 2020. Currently, his research focuses on co-translation and degradation in tumor associated macrophage.
Yanyang Shi
Yanyang received his bachelor degree from Nankai University in 2021. He has a great interest in tumor immunology, and he will make every effort to study it.
Yu Xia
I earned my Bachelor degree of Bioscience at Shanghai Jiao Tong University in 2020. My research interests center around the interaction between antigen presenting cells and T cells.
Zihao Zhang
Zihao Zhang obtained his Bachelor’s degree form Shandong University and started his research in Tsinghua University at 2020. Currently, his research focuses on the epigenetic regulatory network during CD8+ T cells’ differentiation process.
Our goal is to unravel the complex interactions between immune cells, tumor cells and tumor microenvironment (TME) in different cancer settings, thereby developing novel anticancer immunotherapies to improve clinical benefit. We are particularly focusing on how mRNA epitranscriptome and post-transcriptional regulation determine the fate and function of immune cells that impacts antitumor immunity.
ORCID:
ResearcherID:
Selected Publications:
1、Lihui Dong, Chuanyuan Chen, Yawei Zhang, Peijin Guo, Zhenghang Wang, Jian Li, Yi Liu, Jun Liu, Renbao Chang, Yilin Li, Guanghao Liang, Weiyi Lai, Mengxue Sun, Urszula Dougherty, Marc B. Bissonnette, Hailin Wang, Lin Shen, Meng Michelle Xu*, Dali Han*. The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth. Cancer Cell 2021, 39(7):945-957.
2、Yi Liu, Guanghao Liang, Hongjiao Xu, Wenxin Dong, Ze Dong, Zhiwei Qiu, Zihao Zhang, Fangle Li, Yue Huang, Yilin Li, Jun Wu, Shenyi Yin, Yawei Zhang, Peijin Guo, Jun Liu, Jianzhong Jeff Xi, Peng Jiang, Dali Han*, Cai-Guang Yang*, Meng Michelle Xu*. Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metabolism 2021, 33(6):1121-1233.
3、Dali Han*, Jun Liu, Chuanyuan Chen, Lihui Dong, Yi Liu, Renbao Chang, Xiaona Huang, Yuanyuan Liu, Jianying Wang, Urszula Dougherty, Marc B. Bissonnette, Bin Shen, Ralph R Weichselbaum, Meng Michelle Xu*, Chuan He*. Anti-tumour immunity controlled through mRNA m6A methylation and YTHDF1 in dendritic cells. Nature 2019, 566(7743):270-274.
4、Meng Michelle Xu, Yang Pu, Dali Han, Yaoyao Shi, Xuezhi Cao, Hua Liang, Xiang Chen, Xiao-Dong Li, Liufu Deng, Zhijian J. Chen, Ralph R. Weichselbaum, Yang-Xin Fu*. Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein α signaling. Immunity 2017, 47(2):363-373.
5、Meng Michelle Xu, Yang Pu, Ralph R. Weichselbaum*, Yang-Xin Fu*.Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene 2017, 36(5):585-592.
6、Yang Pu, Meng Xu, Yong Liang, Kaiting Yang, Yajun Guo, Xuanming Yang*, Yang-Xin Fu*. Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Science Translational Medicine 2016, 8(333):333ra47.
7、Meng Michelle Xu, Yang Pu, Yuan Zhang, Yang-Xin Fu*. The role of adaptive immunity in the efficacy of targeted cancer therapies. Trends in immunology 2016, 37(2): 141-153.
8、Xiaojuan Liu#, Yang Pu, Kyle Cron, Liufu Deng, Justin Kline, William A. Frazier, Hairong Xu, Hua Peng, Yang-Xin Fu*, Meng Michelle Xu#*. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nature Medicine 2015, 21(10):1209-1215.
9、Meng Xu#, Mingyue Liu#, Xuexiang Du, Sirui Li, Hang Li, Xiaozhu Li, Ying Li, Yang Wang, Zhihai Qin, Yang-Xin Fu*, Shengdian Wang*. Intratumoraldelivery of IL-21 overcomes anti-Her2/Neu resistance through shifting tumor-associated macrophages from M2 to M1 phenotype. The Journal of Immunology 2015, 194(10):4997-5006.
10、Liufu Deng, Hua Liang, Meng Michelle Xu, Xuanming Yang, Byron Burnette, Ainhoa Arina, Xiao-Dong Li, Helena Mauceri, Michael Beckett, Thomas Darga, Xiaona Huang, Thomas F. Gajewski, Zhijian J. Chen, Yang-Xin Fu*, Ralph R. Weichselbauman*. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41(5):843-852.
Copyright © 2017 Institute for Immunology Tsinghua University
Contact Address: Room D302, Medical Science Building, Tsinghua University, Beijing 100084, China
Tel: (86) 10-62776420 Fax: (86) 10-62776420
